Germline gene editing “for the purpose of creating humans” is banned and can be punishable with up to four years imprisonment or fines under the Prohibition of Genetic Intervention Law, passed in 1999 and since renewed multiple times by the Israeli Parliament. However, the Minister of Health may give permission for germline gene editing experiments, […]
Israel: Germline / Embryonic Read More »
Gene therapy is permitted, but must be approved by a human research advisory committee and a dedicated advisory committee (made up of physicians, scientists, regulators and ethics experts) and must follow regulations outlined in the Genetic Information Law. The creation of embryos specifically for stem-cell research is banned, but researchers can use embryos left over
Israel: Therapeutic / Stem Cell Read More »
Gene therapy is permitted, but clinical trials require a license from the Medicines and Healthcare products Regulatory Agency (MHRA) as well as oversight from the Human Tissue Authority (HTA) and the Health Research Authority (HRA). Gene therapy is an experimental technique that uses genes to allow doctors to treat or prevent a disorder by inserting
United Kingdom: Therapeutic / Stem Cell Read More »
Gene editing research in human embryos is permitted, but requires a license from the Human Fertilisation and Embryology Authority (HFEA). Gene editing for reproductive purposes is illegal. In 2016, HFEA permitted the first sanctioned studies applying CRISPR to human embryos, although scientists are permitted to only study embryos for research purposes and are prohibited from
United Kingdom: Germline / Embryonic Read More »
Gene therapy is allowed and clinical trials only require approval by an ethics committee of a hospital. Approval from national regulatory agencies is not required. Research ethics committees are responsible for ensuring compliance by performing ethical review of their institutions’ biomedical research activities involving human research participants. However, there is uncertainty about whether these regulations
China: Therapeutic / Stem Cell Read More »
Germline gene editing research is allowed, but establishing a pregnancy with a genetically engineered embryo is prohibited under multiple regulations. Gene editing requires approval by an ethics committee of a hospital or IVF clinic, but approval from national regulatory agencies is not required. Research ethics committees are responsible for ensuring compliance by performing ethical review
China: Germline / Embryonic Read More »
Germline gene editing for clinical purposes is banned, but it is unclear whether this ban applies to germline gene editing research. Germline editing is regulated by the EU Commission, the European Medicines Agency (EMA) and the Federation of European Academies of Medicine (FEAM). In 2014, the EU Clinical Trials Regulation banned any gene therapy clinical
European Union: Germline / Embryonic Read More »
Gene therapy is permitted but must comply with clinical trial regulations, the EU Commission Regulation on advanced therapy medicinal products, and the European GMO Directive, written in 2001, that outlines regulations for organisms altered through genetic modification. Requirements include environmental risk assessments and assessments on the potential adverse effects on human health. In addition, the
European Union: Therapeutic / Stem Cell Read More »
Germline gene editing is banned by a resolution and a law. The CNS Resolution #340, finalized in 2004, allows human genetic research on somatic (adult) cells only. In 2005, Law No. 11.105 was passed, which bans genetic engineering in “human germinal cells, human zygotes and human embryos”. However, the law primarily focuses on regulating genetically
Brazil: Germline / Embryonic Read More »
In 2019, a measure was approved by the Brazilian Health Regulatory Agency (Anvisa) to regulate gene therapy as a drug and to establish specific criteria for clinical studies using gene therapy. Because the measure clarified the approval process for gene therapy research, it is expected to increase gene therapy research being conducted. Additional legislation is
Brazil: Therapeutic / Stem Cell Read More »
Gene editing is a set of techniques that can be used to precisely modify the DNA of almost any organism. It is being used for applications in human health, gene drives and agriculture. There are numerous gene-editing tools besides CRISPR-Cas 9, which gets most of the attention because it is a comparatively easy tool to use.
Gene editing does not usually involve transgenics – moving ‘foreign’ genes between species. It also refers to a specific technique in contrast to the general term GMO, which is scientifically ambiguous, as genetic modification is a process not a product. Most gene editing involves creating new products by deleting very small segments of DNA (sometimes in agriculture called Site-Directed Nuclease 1 or SDN-1 techniques), which can silence a gene or change a gene’s activity. Countries are evaluating whether or not to regulate this type of gene editing, since it is so similar to natural mutations. The GLP’s Gene Editing Index ratings reflect the regulatory status of SDN-1 techniques, which are the most liberally regulated and will generate most products in the near term.
To develop different products, gene editing can change larger segments of DNA or add DNA from other species (a form of transgenics sometimes in agriculture called SDN-2 or SDN-3 techniques). While many countries are not regulating or lightly regulating SDN-1 techniques, most are moving toward tightly regulating or even restricting SDN-2 and SDN-3.
For more background on the various gene editing SDN techniques, read background articles here and here.